Latigo Biotherapeutics Reports Third-Quarter 2026 EPS of ($0.55)
The company’s net loss narrowed year over year as lower research and development spending more than offset higher general and administrative expenses. Other income also improved.
The company’s net loss narrowed year over year as lower research and development spending more than offset higher general and administrative expenses. Other income also improved.